The maximum standardized uptake value (SUVmax) on FDG-PET is a strong predictor of local recurrence for localized non-small-cell lung cancer after stereotactic body radiotherapy (SBRT)

Radiotherapy and Oncology

Volumn 101, Issue 2, 2011, Pages 291-297

  Takeda, Atsuya ^a   Yokosuka, Noriko ^b   Ohashi, Toshio ^a,c   Kunieda, Etsuo ^d   Fujii, Hirofumi ^e   Aoki, Yousuke ^a   Sanuki, Naoko ^a   Koike, Naoyoshi ^a   Ozawa, Yukihiko ^b  

^a Ofuna Chuo Hospital   (Japan)

^b Yuai Clinic   (Japan)

^c KEIO UNIVERSITY   (Japan)

^d TOKAI UNIVERSITY   (Japan)

^e NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

Author keywords

FDG PET; Local recurrence; Lung cancer; Maximum standardized uptake value; SMRT SUVmax; Stereotactic body radiotherapy

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER STAGING; FEMALE; FOLLOW UP; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MAXIMUM STANDARDIZED UPTAKE VALUE; POSITRON EMISSION TOMOGRAPHY; PREDICTOR VARIABLE; PRIORITY JOURNAL; RADIATION DOSE; RADIOLOGICAL PARAMETERS; RETROSPECTIVE STUDY; STEREOTACTIC BODY RADIATION THERAPY; TUMOR VOLUME;

AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; RADIOSURGERY; TREATMENT OUTCOME;

EID: 81755179382     PISSN: 01678140     EISSN: 18790887     Source Type: Journal    
DOI: 10.1016/j.radonc.2011.08.008     Document Type: Article

References (45)

1. M. Uematsu, A. Shioda, and A. Suda Computed tomography-guided frameless stereotactic radiotherapy for stage I non-small cell lung cancer: a 5-year experience Int J Radiat Oncol Biol Phys 51 2001 666 670
2. H. Onishi, T. Araki, and H. Shirato Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multiinstitutional study Cancer 101 2004 1623 1631 (Pubitemid 39318910)
3. K. Takayama, Y. Nagata, and Y. Negoro Treatment planning of stereotactic radiotherapy for solitary lung tumor Int J Radiat Oncol Biol Phys 61 2005 1565 1571 (Pubitemid 40470441)
4. A. Takeda, N. Sanuki, and E. Kunieda Stereotactic body radiotherapy for primary lung cancer at a dose of 50 Gy total in five fractions to the periphery of the planning target volume calculated using a superposition algorithm Int J Radiat Oncol Biol Phys 73 2009 442 448
5. Y. Matsuo, K. Takayama, and Y. Nagata Interinstitutional variations in planning for stereotactic body radiation therapy for lung cancer Int J Radiat Oncol Biol Phys 68 2007 416 425 (Pubitemid 46711148)
6. R. Timmerman, R. McGarry, and C. Yiannoutsos Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer J Clin Oncol 24 2006 4833 4839 (Pubitemid 46630909)
7. R.M. Pieterman, J.W. van Putten, and J.J. Meuzelaar Preoperative staging of non-small-cell lung cancer with positron-emission tomography N Engl J Med 343 2000 254 261 (Pubitemid 30490393)
8. E.M. Toloza, L. Harpole, and D.C. McCrory Noninvasive staging of non-small cell lung cancer: a review of the current evidence Chest 123 2003 137S 146S (Pubitemid 36135711)
9. S. Sadahiro, T. Suzuki, and K. Ishikawa Recurrence patterns after curative resection of colorectal cancer in patients followed for a minimum of ten years Hepatogastroenterology 50 2003 1362 1366 (Pubitemid 37186484)
10. A. Takeda, E. Kunieda, and N. Shigematsu Small lung tumors: long-scan-time CT for planning of hypofractionated stereotactic radiation therapy - initial findings Radiology 237 2005 295 300 (Pubitemid 41346177)
11. A. Takeda, E. Kunieda, and N. Sanuki Dose distribution analysis in stereotactic body radiotherapy using dynamic conformal multiple arc therapy Int J Radiat Oncol Biol Phys 74 2009 363 369
12. A. Takeda, E. Kunieda, and T. Takeda Possible misinterpretation of demarcated solid patterns of radiation fibrosis on CT scans as tumor recurrence in patients receiving hypofractionated stereotactic radiotherapy for lung cancer Int J Radiat Oncol Biol Phys 70 2008 1057 1065 (Pubitemid 351296119)
13. X. Qiao, O. Tullgren, I. Lax, F. Sirzen, and R. Lewensohn The role of radiotherapy in treatment of stage I non-small cell lung cancer Lung Cancer 41 2003 1 11 (Pubitemid 36765477)
14. S. Senan, and F. Lagerwaard Stereotactic radiotherapy for stage I lung cancer: current results and new developments Cancer Radiother 14 2010 115 118
15. A. Chi, Z. Liao, N.P. Nguyen, J. Xu, B. Stea, and R. Komaki Systemic review of the patterns of failure following stereotactic body radiation therapy in early-stage non-small-cell lung cancer: clinical implications Radiother Oncol 94 2010 1 11
16. H. Onishi, H. Shirato, and Y. Nagata Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study J Thorac Oncol 2 2007 S94 100
17. P. Baumann, J. Nyman, and I. Lax Factors important for efficacy of stereotactic body radiotherapy of medically inoperable stage I lung cancer. A retrospective analysis of patients treated in the Nordic countries Acta Oncol 45 2006 787 795 (Pubitemid 44423123)
18. R. Onimaru, M. Fujino, and K. Yamazaki Steep dose-response relationship for stage I non-small-cell lung cancer using hypofractionated high-dose irradiation by real-time tumor-tracking radiotherapy Int J Radiat Oncol Biol Phys 70 2008 374 381
19. M. Koto, Y. Takai, and Y. Ogawa A phase II study on stereotactic body radiotherapy for stage I non-small cell lung cancer Radiother Oncol 85 2007 429 434 (Pubitemid 350213143)
20. J.M. Brown, M. Diehn, and B.W. Loo Jr. Stereotactic ablative radiotherapy should be combined with a hypoxic cell radiosensitizer Int J Radiat Oncol Biol Phys 78 2010 323 327
21. L. Feuvret, I. Germain, and P. Cornu First treatment for brain metastases by stereotactic radiosurgery Bull Cancer 86 1999 666 672
22. M. Paesmans, T. Berghmans, and M. Dusart Primary tumor standardized uptake value measured on fluorodeoxyglucose positron emission tomography is of prognostic value for survival in non-small cell lung cancer: update of a systematic review and meta-analysis by the European Lung Cancer Working Party for the International Association for the Study of Lung Cancer Staging Project J Thorac Oncol 5 2010 612 619
23. K. Higashi, Y. Ueda, and Y. Arisaka 18F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer J Nucl Med 43 2002 39 45 (Pubitemid 34101186)
24. R. Sasaki, R. Komaki, and H. Macapinlac [18F]fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer J Clin Oncol 23 2005 1136 1143 (Pubitemid 46202269)
25. S.J. Kim, Y.K. Kim, I.J. Kim, Y.D. Kim, and M.K. Lee Limited prognostic value of dual time point F-18 FDG PET/CT in patients with early stage (stage I & II) non-small cell lung cancer (NSCLC) Radiother Oncol 98 2011 105 108
26. R.J. Downey, T. Akhurst, M. Gonen, B. Park, and V. Rusch Fluorine-18 fluorodeoxyglucose positron emission tomographic maximal standardized uptake value predicts survival independent of clinical but not pathologic TNM staging of resected non-small cell lung cancer J Thorac Cardiovasc Surg 133 2007 1419 1427
27. H. Vesselle, J.D. Freeman, and L. Wiens Fluorodeoxyglucose uptake of primary non-small cell lung cancer at positron emission tomography: new contrary data on prognostic role Clin Cancer Res 13 2007 3255 3263 (Pubitemid 46944910)
28. M. Agarwal, G. Brahmanday, S.K. Bajaj, K.P. Ravikrishnan, and C.Y. Wong Revisiting the prognostic value of preoperative (18)F-fluoro-2-deoxyglucose ((18)F-FDG) positron emission tomography (PET) in early-stage (I & II) non-small cell lung cancers (NSCLC) Eur J Nucl Med Mol Imaging 37 2010 691 698
29. H.J. Aerts, A.A. van Baardwijk, and S.F. Petit Identification of residual metabolic-active areas within individual NSCLC tumours using a pre-radiotherapy (18)fluorodeoxyglucose-PET-CT scan Radiother Oncol 91 2009 386 392
30. S.F. Petit, H.J. Aerts, and J.G. van Loon Metabolic control probability in tumour subvolumes or how to guide tumour dose redistribution in non-small cell lung cancer (NSCLC): an exploratory clinical study Radiother Oncol 91 2009 393 398
31. A. Abramyuk, S. Tokalov, and K. Zophel Is pre-therapeutical FDG-PET/CT capable to detect high risk tumor subvolumes responsible for local failure in non-small cell lung cancer? Radiother Oncol 91 2009 399 404
32. D.J. Hoopes, M. Tann, and J.W. Fletcher FDG-PET and stereotactic body radiotherapy (SBRT) for stage I non-small-cell lung cancer Lung Cancer 56 2007 229 234 (Pubitemid 46590486)
33. M.J. Burdick, K.L. Stephans, C.A. Reddy, T. Djemil, S.M. Srinivas, and G.M. Videtic Maximum standardized uptake value from staging FDG-PET/CT does not predict treatment outcome for early-stage non-small-cell lung cancer treated with stereotactic body radiotherapy Int J Radiat Oncol Biol Phys 78 2010 1033 1039
34. F. Dehdashti, M.A. Mintun, and J.S. Lewis In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM Eur J Nucl Med Mol Imaging 30 2003 844 850 (Pubitemid 36734203)
35. J.W. Kim, P. Gao, and C.V. Dang Effects of hypoxia on tumor metabolism Cancer Metastasis Rev 26 2007 291 298 (Pubitemid 47103157)
36. A. Giatromanolaki, M.I. Koukourakis, and E. Sivridis Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer Cancer Res 61 2001 7992 7998 (Pubitemid 33049392)
37. R. Boellaard Standards for PET image acquisition and quantitative data analysis J Nucl Med 50 2009 11S 20S
38. D.E. Swinson, J.L. Jones, and D. Richardson Carbonic anhydrase IX expression, a novel surrogate marker of tumor hypoxia, is associated with a poor prognosis in non-small-cell lung cancer J Clin Oncol 21 2003 473 482 (Pubitemid 46613490)
39. M.I. Koukourakis, S.M. Bentzen, and A. Giatromanolaki Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial J Clin Oncol 24 2006 727 735 (Pubitemid 46622039)
40. H. Vesselle, R.A. Schmidt, and J.M. Pugsley Lung cancer proliferation correlates with [F-18]fluorodeoxyglucose uptake by positron emission tomography Clin Cancer Res 6 2000 3837 3844
41. H. Vesselle, A. Salskov, and E. Turcotte Relationship between non-small cell lung cancer FDG uptake at PET, tumor histology, and Ki-67 proliferation index J Thorac Oncol 3 2008 971 978
42. A. van Baardwijk, C. Dooms, and R.J. van Suylen The maximum uptake of (18)F-deoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor-1alpha and GLUT-1 in non-small cell lung cancer Eur J Cancer 43 2007 1392 1398 (Pubitemid 46874072)
43. J.S. Scheuermann, J.R. Saffer, J.S. Karp, A.M. Levering, and B.A. Siegel Qualification of PET scanners for use in multicenter cancer clinical trials: the American College of Radiology Imaging Network experience J Nucl Med 50 2009 1187 1193
44. F.J. Lagerwaard, C.J. Haasbeek, E.F. Smit, B.J. Slotman, and S. Senan Outcomes of risk-adapted fractionated stereotactic radiotherapy for stage I non-small-cell lung cancer Int J Radiat Oncol Biol Phys 70 2008 685 692
45. N.C. van der Voort van Zyp, J.B. Prevost, and M.S. Hoogeman Stereotactic radiotherapy with real-time tumor tracking for non-small cell lung cancer: clinical outcome Radiother Oncol 91 2009 296 300